Metaxalone Formulation Dissolution Control for Food-Effect Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Metaxalone formulations experience a significant food effect, leading to increased Cmax, AUC, and altered Tmax and half-life when taken with a high-fat meal, limiting administration to the fasted state and impairing drug utility.
Innovation Solution
Formulations meeting specified dissolution criteria in 0.5% Sodium Lauryl Sulfate (SLS) and Fasted State Simulated Intestinal Fluid (FaSSIF) or pH 4.5 and 6.0 buffer dissolution media, using a combination of micronized and non-micronized particles, and excipients like propylene glycol alginate, to maintain bioavailability in both fed and fasted states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If metaxalone is administered with a high-fat meal, then Cmax and AUC increase significantly, but this food effect limits administration to the fasted state and impairs drug utility
Solution Approach 1:
The patent modifies the dissolution rate parameters of metaxalone formulations to achieve consistent bioavailability across different feeding states. By controlling the dissolution rate to fall within specific ranges (50-85% in fasted state, 70-95% in fed state), the formulation maintains reliable drug release regardless of food presence, thereby improving bioavailability consistency while enabling administration flexibility
Solution Approach 2:
The patent applies preliminary action by pre-modifying the metaxalone formulation with specific excipients and processing methods before administration. The formulation is prepared in advance with controlled dissolution characteristics that will maintain consistent bioavailability regardless of whether food is present during administration, thus resolving the contradiction between reliability and ease of operation
2Reliability
If metaxalone dissolution rate is increased to improve bioavailability, then Cmax increases, but Tmax is delayed and terminal half-life is decreased
Solution Approach 1:
The patent optimizes the dissolution rate parameters to achieve a balanced profile. By controlling the dissolution rate to specific ranges rather than maximizing it, the formulation achieves adequate bioavailability (Cmax) while maintaining appropriate absorption kinetics that preserve terminal half-life duration, thus resolving the contradiction between bioavailability improvement and duration maintenance
3Object-affected harmful factors
If a reduced dose of metaxalone is used, then the risk of side effects decreases, but the therapeutic efficacy may be compromised without improved bioavailability
Solution Approach 1:
The patent changes the bioavailability parameters of metaxalone through formulation modifications. This enhanced bioavailability allows a lower dose (640 mg instead of 800 mg) to achieve the same therapeutic effect, thereby reducing side effect risk while maintaining therapeutic efficacy. The controlled dissolution rate ensures consistent drug release that maintains efficacy at the reduced dose
Solution Approach 2:
The patent introduces formulation excipients and processing methods as intermediaries that enhance metaxalone bioavailability. These intermediaries facilitate better drug absorption and release characteristics, enabling the reduced dose to be as effective as the higher standard dose while potentially reducing adverse effects
Data Source
AI summary
Oral dosage forms of metaxalone having improved bioavailability in the fed and fasted states, including dosage forms that employ a reduced dose based on such improved bioavailability.